Mustang Bio Q3 2022 net loss $19.0M ($0.18/sh); cash $92.4M; MB-106 trial advances

MUSTANG BIO, INC.

2022-Q3 EPS reported -$0.57

Cash and equivalents $92.4M at Sep 30, 2022, down $16.0M from June 30, $110.6M at Dec 31, 2021.
Net loss attributable to common stockholders $19.0M ($0.18/sh) vs $17.0M ($0.19/sh) in Q3 2021.
First patient treated in Mustang-sponsored multicenter Phase 1/2 trial for MB-106 (CD20 CAR T) in B-NHL and CLL.
Fred Hutch trial: 96% ORR, 75% CR in 28 patients; 12 patients CR >12 months; no Grade ≥3 CRS or ICANS.
MB-106 granted FDA Orphan Drug Designation for Waldenstrom macroglobulinemia; early Phase 1 results expected Dec 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MUSTANG BIO, INC. reported the third quarter ended September 30, 2022 results: net income $19.0 million, or $0.18 per share, EPS $0.18 per share.

Period: the third quarter ended September 30, 2022
Net income: $19.0 million, or $0.18 per share
EPS: $0.18 per share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders was $19.0 million, or $0.18 per share, for the third quarter of 2022

View on SEC.gov

Browse all earnings releases →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001558370-22-017836

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.